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Background: 2,4-Dimethoxyphenyl-E-4-arylidene-3-isochromanone (IK11) was previously described to induce
apoptotic death of A431 tumor cells. In this report, we investigated the molecular action of IK11 in the HepG2
human hepatocellular carcinoma cell line to increase our knowledge of the role of poly (ADP-ribose)-polymerase
(PARP), protein kinase B/Akt and mitogen activated protein kinase (MAPK) activation in the survival and death of
tumor cells and to highlight the possible role of PARP-inhibitors in co-treatments with different cytotoxic agents in
cancer therapy.
Results: We found that sublethal concentrations of IK11 prevented proliferation, migration and entry of the cells
into their G2 phase. At higher concentrations, IK11 induced reactive oxygen species (ROS) production,
mitochondrial membrane depolarization, activation of c-Jun N-terminal kinase 2 (JNK2), and substantial loss of
HepG2 cells. ROS production appeared marginal in mediating the cytotoxicity of IK11 since N-acetyl cysteine was
unable to prevent it. However, the PARP inhibitor PJ34, although not a ROS scavenger, strongly inhibited both IK11-
induced ROS production and cell death. JNK2 activation seemed to be a major mediator of the effect of IK11 since
inhibition of JNK resulted in a substantial cytoprotection while inhibitors of the other kinases failed to do so.
Inhibition of Akt slightly diminished the effect of IK11, while the JNK and Akt inhibitor and ROS scavenger trans-
resveratrol completely protected against it.
Conclusions: These results indicate significant involvement of PARP, a marginal role of ROS and a pro-apoptotic
role of Akt in this system, and raise attention to a novel mechanism that should be considered when cancer
therapy is augmented with PARP-inhibition, namely the cytoprotection by inhibition of JNK2.
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PARP-1 is a nuclear enzyme present in eukaryotes in a
high copy number. One of its major physiological functions
is responding to single- and double-strand DNA breaks
and facilitating DNA repair. Inhibition of PARP-1 sensitizes
cells to DNA-damaging agents [1] indicating its potential-
ity in facilitating tumor therapy. Furthermore, it was shown
that cells deficient in breast cancer associated gene-1 and
−2 (BRCA1/2) are extremely sensitive to PARP-1 inhibition
because of the defective double-strand DNA break repair
[2] in these cells. Therefore, PARP inhibition is considered
as a useful therapeutic strategy not only for the treatment
of BRCA mutation-associated tumors, but also for the
treatment of a wider range of tumors bearing a variety of
deficiencies in the homologous recombination DNA repair
pathway [3]. PARP inhibitors were also found to protect
cells and tissues in different pathophysiological conditions
[4] by various mechanisms including activation of the cyto-
protective phosphatidylinositol-3 kinase (PI3K)-Akt path-
way [5] that could even impair the efficacy of tumor
therapy and mediate drug-resistance [6,7].
Besides the Akt pathway, PARP activation was asso-
ciated with all three branches of mitogen activated protein
kinases (MAPKs); the c-jun N-terminal kinase (JNK) [8],
the p38 [8] and the extracellular signal regulated kinase
(ERK) [9]. The latter is the main transducer of growth
stimuli [9]; however, its role in the apoptosis inducing
mechanism of cytotoxic agents appears to be more com-
plex. On one hand, inhibition of ERK1/2 activity has been
shown to increase the sensitivity of ovarian carcinoma
cells against cisplatin [10], but on the other hand, activa-
tion of ERK1/2 was found to be required in cisplatin-
induced apoptosis e.g. in renal proximal tubule cells [11].
The role of JNK and p38 cascades seems more straightfor-
ward. Mostly, they are associated with mediating the
apoptotic signal, and their activation leads to cell death in
various stress situations such as oxidative stress and in-
flammation [12].
Recently, we proposed that PARP activation in oxidative
stress leads to suppression of MAPK phosphatase-1 (MKP-
1) and thereby to the activation of p38 and JNK [13]. Acti-
vation of PARP and/or MAPKs could lead to mitochondrial
depolarization [8,9,14]. Depolarization can result in the re-
lease of mitochondrial intermembrane proteins, triggering
apoptosis, or in the permeability transition pore-dependent
failure of ATP generation, leading to necrosis [15]. Accord-
ingly, various mediators and regulators of mitochondrial
depolarization-dependent cell death were suggested as tar-
gets in tumor therapy since mitochondrial mechanisms
could facilitate either reversion of apoptotic resistance [16]
or induction of necrosis via activation of permeability tran-
sition in the apoptosis-resistant tumor cells [17,18].
2,4-Dimethoxyphenyl-E-4-arylidene-3-isochromanone
(IK11) was previously described to induce PARP cleavagedependent apoptosis in A431 tumor cell with high efficacy
[19]. This finding suggested that the mechanism of IK11
induced cell death could be different from that of other
substances used in previous studies. Although excessive
over-activation of PARP is generally associated with nec-
rotic cell death, over-activation of a lower extent could
trigger apoptosis [4]. On the other hand, PARP cleavage is
considered as an early indicator of the caspase dependent
apoptotic process. Therefore, it seemed worth investigat-
ing how the PARP inhibitor PJ34 affected the IK11
induced cell death process. To this end, we determined
the effect of IK11 on cell migration, apoptosis, necrosis,
mitochondrial depolarization, reactive oxygen species
(ROS) production as well as Akt and MAPK activation in
HepG2 human hepatocellular carcinoma cells. Further-
more, we studied how inhibitors of PARP and intracellular
kinase signaling pathways, and the antioxidant N-acetyl
cysteine (NAC) affected the IK11 induced cell death
process.Materials and methods
Reagents
Primary antibodies, namely anti-phospho-Akt (S473),
anti-phospho-p38 MAP-Kinase (T180/Y182), anti-
phospho-p44/42 MAPK (T202/Y204) were from Cell Sig-
naling Technology, anti-phospho-JNK (T183/Y185) from
R&D System and anti-glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) we obtained from Millipore. The
used kinase pathway inhibitors, namely Akt pathway inhi-
bitors (LY294002, Akt inhibitor IV.) and JNK inhibitor
(SP600125) were purchased from Calbiochem. All other
substances including trans-resveratrol and PJ34 were from
Sigma-Aldrich. IK11, was synthesized by us [20] and was
dissolved in dimethyl-sulphoxide (DMSO) at 1000 times
of the final concentration used. HO3089 [21] and L2286
[22] were kind gift of professor Kalman Hideg Department
of Organic and Pharmacological Chemistry, University of
Pecs Medical School, Pecs, Hungary.
Cell culture
HepG2 human hepatocellular carcinoma cells obtained
from European Collection of Cell Cultures were cultured
in 5% CO2 at 37°C in Dulbecco’s Modified Eagle’s Medium
supplemented with 10% fetal calf serum. Cells were seeded
at a starting density of 2 × 104 cells/well in a 96-well plate
for viability and ROS production assays, or of 2 × 106
cells/well in a 6-well plate for immunoblotting and deter-
mination of cell morphology. Full confluent 6 well plates
were used for migration assay.
Silencing of PARP by siRNA technique
HepG2 cells were transiently transfected with siRNA
designed for PARP suppression by the manufacturer (Santa
Radnai et al. Molecular Cancer 2012, 11:34 Page 3 of 12
http://www.molecular-cancer.com/content/11/1/34Cruz Biotechnology, Santa Cruz, CA) in Opti-MEM I
Reduced Serum Medium (Invitrogen) using Lipofectamine
2000. For an effective suppression of PARP, the transfection
step was repeated twice with a 48-h interval between the
transfections, and the experiments on the cells were per-
formed 40 h after the third transfection.
Determination of intracellular reactive oxygen species
Intracellular ROS were determined using the oxidation-
sensitive 2,4 dichlorodihydrofluorescein-diacetat (C-400)
fluorescent dye. Cells were seeded into 96-well plates
and cultured overnight. After subjecting the cells to the
treatment indicated in the figure legends, medium was
replaced to a fresh one containing 2 μg/ml C400. Incu-
bation was continued for an additional 2 hrs to allow
oxidation of C-400 by the endogenous ROS. Fluores-
cence of oxidized C-400 was excited at 485 nm and the
evoked emission was measured at 555 nm by using a
FLUOstar Optima fluorescent plate-reader. All experi-
ments were run in at least 6 parallels and repeated three
times.
Cell viability assay
Cells were seeded and treated as for ROS determination.
After the treatment, medium was replaced to a fresh one
containing 0.5% MTT. Incubation was continued for an
additional 3 h, and the reduction of MTT to formasan
was terminated by adding isopropanol containing 0.4%
HCl. The concentration of the water-insoluble formasan
dye was proportional to the number of living cells. After
dissolving the dye in the acidified isopropanol, the ab-
sorption was measured with an Anthos Labtech 2010
plate-reader at 550 nm wavelength. All experiments
were run in 6 parallels and repeated three times.
Immunoblot analysis
The cells were seeded into a 6-well plate and cultured over-
night. After subjecting the cells to the treatment indicated
in the figure legends for 6 h, the cells were harvested in
ice-cold lysis buffer containing 0.5 mM sodium metavana-
date, 1 mM ethylenediaminetetraacetic acid (EDTA), and
protease inhibitor mixture in phosphate-buffered saline
(PBS). The proteins were precipitated by trichloroacetic
acid, washed three times with −20°C acetone, and sub-
jected to sodium-dodecylsulphate polyacrylamide gel elec-
trophoresis. Proteins (20 μg/lane) were separated on 12%
gels and then transferred to nitrocellulose membranes.
The membranes were blocked in 5% low fat milk for 1 h
at room temperature and were exposed to the primary
antibodies at 4°C overnight at a dilution of 1:1000 in
blocking solution. Appropriate horseradish peroxidase-
conjugated secondary antibodies were used for 2 h at
room temperature in 1:5000 dilution. Peroxidase labeling
was visualized with enhanced chemiluminescence usingthe SuperSignal West Pico chemiluminescent substrate
(Pierce Chemical).
Monolayer wound healing assay
HepG2 cells were seeded in six well plates and cul-
tured until reaching full confluency. Then two per-
pendicular lines were drawn at the bottom of the well
with a 1000 μl pipette tip. These lines served as
marks for the wound areas to be analyzed. Then the
medium was changed to a fresh one containing 1 μM
IK11 for an additional 24 hrs incubation before taking
images from a section of the wounds directly above
the intercept of the two lines by a Zeiss Axiovert 25
microscope equipped with a ProgRes C12 Plus CCD
camera using a 10x phase-contrast objective. All
experiments were repeated three times.JC-1 assay for fluorescent microscopy
Mitochondrial membrane potential (ΔΨm) was mea-
sured using the mitochondrial membrane potential
specific fluorescent probe, JC-1 (Molecular Probes).
HepG2 cells were seeded to glass coverslips and cul-
tured at least overnight before the experiment. After
the indicated treatment, cells were washed twice in
ice-cold PBS, and then incubated for 5 min at 37°C
in PBS containing 2 μM JC-1. When excited at
490 nm, the dye will emit green fluorescence at low
ΔΨm and red at high ΔΨm. Following incubation, the
cells were washed once with PBS, then were imaged
with a Zeiss Axiovert 25 fluorescent microscope
equipped with a ProgRes C12 Plus CCD camera using
a 63x objective and epifluorescent illumination. All
experiments were repeated three times.JC-1 assay for flow cytometry
JC-1 assay kit for flow cytometry was used to detect
mitochondrial depolarization in cultured HepG2 cells
(Invitrogen, Molecular Probes, Hungary). After the
indicated treatment, cells were incubated in the pres-
ence of 2 μM JC-1 for 5 min. Cells were washed once
with PBS, then were immediately analyzed by a BD
FacsCalibur flow cytometer (BD Biosciences, USA).
Data were accumulated and reduced by Cellquest
software (BD Biosciences, USA). JC-1 is accumulated
in the mitochondria in a potential-dependent manner,
indicated by a fluorescence emission shift from red
(590 nm) to green (529 nm) upon depolarization.
Consequently, mitochondrial depolarization is indi-
cated by decrease in the red/green fluorescence inten-
sity ratio. Cells in each category were expressed as
percentage of the total number of stained cells
counted. All experiments were repeated three times.
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cytometry
Apoptosis was assessed after double staining with fluor-
escein isothiocyanate (FITC)-labeled annexin V (BD
Biosciences, Hungary) and propidium iodide (PI; BD
Biosciences, Hungary) using flow cytometry. First, the
medium was discarded and the wells were washed twice
with isotonic sodium chloride solution. Cells were
removed from the plates using a mixture of 0.25% tryp-
sin, 0.2% EDTA, 0.296% sodium citrate, 0.6% sodium
chloride in distilled water. This medium was applied for
15 min at 37°C. Removed cells were washed twice in
cold PBS and were resuspended in binding buffer con-
taining 10 mM Hepes NaOH, pH 7.4, 140 mM NaCl,
2.5 mM CaCl2. Cell-count was determined in Burker's
chamber. 100μL of buffer containing 105 cells was trans-
ferred into 5 ml round-bottom polystyrene tubes. Cells
were incubated for 15 min with FITC-conjugated
annexin V and propidium iodide (PI). After this period of
incubation, 400 μl of annexin-binding buffer (BD Bios-
ciences, Hungary) was added to the tubes as described by
the manufacturer. The samples were immediately mea-
sured by BD FacsCalibura a flow cytometer. Results were
analyzed by Cellquest software (BD Biosciences, USA).
Quadrant dot plot was introduced to identify living and
necrotic cells and cells in early or late phase of apoptosis.
Necrotic cells were identified as single PI-positive. Apop-
totic cells were branded as annexin V-FITC-positive only
and cells in late apoptosis were recognized as double-
positive for annexin V-FITC and PI. Cells in each category
were expressed as percentage of the total number of
stained cells counted. All experiments were repeated three
times.
Cell cycle analysis with flow cytometry
Cell cycle analysis was performed using HepG2 cell line.
HEpG2 cells were synchronized by serum deprivation prior
to experiments in incomplete culture media overnight. Fol-
lowing treatments, the samples were fixed and permeabi-
lized in 75% alcohol. The samples were washed and
incubated in the staining media (PBS containing 10 μg/ml
PI and 100 μg/ml RNAse A) for 1 h at 4°C. DNA content
of the cells was measured on a FACSCalibur flow cyt-
ometer. Data were analyzed by FCS Express Version 3 soft-
ware. All experiments were repeated three times.
Statistical analysis
Values are presented as means ± SEM. Data were ana-
lyzed using 1-way ANOVA followed by Bonferroni’s test.
Differences were considered significant at P< 0.05.
HepG2 cells were treated with 1000 times diluted DMSO
as vehicle control (0) or with 0.1-10 μM 2,4-dimethoxyphe-
nyl-E-4-arylidene-3-isochromanone (IK11) (A) for 24 hrs.
Viability of the cells (B) was determined by MTT methodin 96-well plates. Data are expressed as means±SEM of
three independent experiments running in six parallels.
Small case Latin letters above the bars indicate significant
differences. Means for a variable without a common letter
differ, P< 0.05.
Alternatively, HepG2 cells were cultured until con-
fluency in 6-well plates, then were treated or not (CTRL)
with 1 μM IK11 for 24 hrs. Cell migration (C) was deter-
mined by comparing microscopic images of a monolayer
wound taken at the beginning (0 h) and the end (24 h)
of the incubation period. Representative images are
shown; results of the 3 sets of independent experiments
were basically identical.
Another aliquot of HepG2 cells were treated or not
(open bars) with 0.5 μM (grey bars) or 1 μM (black bars)
IK11 for 24 hrs in 6-well plates. Percentage of cells in
G1, S and G2 phase of their cycle (D) was assessed by
measuring their respective DNA content using a FACS
Calibur flow cytometer. Results are expressed in percen-
tages of the total number of cells means ± SEM of three
independent experiments.
Small case Latin letters above the bars indicate signifi-
cant differences. Means for a variable without a common
HepG2 cells were treated with 1000 times diluted letter
differ, P< 0.05.
HepG2 cells were treated with 1000 times diluted
DMSO as vehicle control (CTRL) or with 10 μM IK11
for 24 hrs. HepG2 cells were treated with DMSO as ve-
hicle control (CTRL) or with 10 μM IK11 for 24 hrs.
Apoptosis and necrosis was determined by flow cytome-
try after double staining the cells with FITC-Annexin V
and propidium iodide. Representative dot-plots (A) are
shown; results of the 3 sets of independent experiments
were basically identical. Data combined from all experi-
ments are expressed as percentages of the total number
of cells, HepG2 cells were treated with 1000 times
diluted and presented in pie chart (B).
HepG2 cells were treated with 1000 times diluted
DMSO as vehicle control (CTRL) or with 10 μM IK11
for 30 min. JC-1 assay kit for flow cytometry (A) was
used to detect mitochondrial depolarization in cultured
HepG2 cells by measuring red (black) and green (grey)
fluorescence intensity. Representative dot-plots are
shown; results of the 3 sets of independent experiments
were basically identical. Data combined from all experi-
ments are expressed as fluorescent intensity in arbitrary
units (a.u.), means ± SEM.
Mitochondrial depolarization was also demonstrated by
using JC-1 fluorescent imaging (B). HepG2 cells were
seeded to glass coverslips and cultured at least overnight
before treating them or not (CTRL) with 10 μM IK11 for
24 hrs. Representative images are shown; results of the 3
sets of independent HepG2 cells were treated with 1000
times diluted experiments were basically identical.
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DMSO as vehicle control (0.0) or with 0.1-10 μM IK11
for 24 hrs. Dose–response of IK11 on intracellular ROS
production (A) was determined by measuring fluores-
cent intensity of C-400 oxidized by the ROS.
Another aliquot of HepG2 cells were treated with
1000 times diluted DMSO as vehicle control (CTRL),
10 μM IK11 or 2 mM NAC (ROS scavenger) in different
combinations as indicated for 24 hrs. Intracellular ROS
production (B) and cell viability (C) was determined by
measuring fluorescent intensity of C-400 oxidized by the
ROS or by the MTT method, respectively. Data are
expressed as means ± SEM of three independent experi-
ments running in six parallels.
Small case Latin letters above the bars indicate signifi-
cant differences. Means for a variable without a common
letter differ, P< 0.05.
HepG2 cells were treated with 1000 times diluted
DMSO as vehicle control (−), 0.1-10 μM IK11 or 10 μM
PJ34 (PARP inhibitor, applied 1 h before the IK11 treat-
ment) in different combinations as indicated for 24 hrs.
Alternatively, PARP was silenced by siRNA technique be-
fore exposure to IK11. Dose–response of IK11 on cell via-
bility (A) and intracellular ROS production (B) in the
presence and absence of PJ34 or PARP silencing was
determined by the MTT method or by measuring fluores-
cent intensity of C-400 oxidized by the ROS, respectively.
Data are expressed as means ± SEM of three independent
experiments running in six parallels.
Small case Latin letters above the bars indicate signifi-
cant differences. Means for a variable without a common
HepG2 cells were treated with 1000 times diluted letter
differ, P< 0.05.
HepG2 cells were treated with 1000 times diluted
DMSO as vehicle control (CTRL), 10 μM IK11 or
10 μM of the PARP inhibitor PJ34 (applied 1 h before
the IK11 treatment) in different combinations as indi-
cated for 6 h. Phosphorylation of JNK and Akt (A) was
analyzed from whole cell extracts by immunoblotting
utilizing phosphorylation-specific primary antibodies.
We used GAPDH as a loading control. Representative
immunoblots as well as band intensity bar diagrams (B)
of 3 independent experiments are presented. Band inten-
sities determined by Image J software and normalized to
band intensities of the loading control were expressed as
means ± SEM.
HepG2 cells were treated with 1000 times diluted
DMSO as vehicle control (CTRL), 10 μM IK11, 10 μM
of the JNK inhibitor SP-600125, 32.54 μM of the Akt
pathway inhibitor LY294002, 5 μM of the specific Akt
inhibitor Akt-inh. IV. or 50 μM of the ROS scavenger,
JNK and Akt inhibitor resveratrol (Resv.) in different
combinations as indicated for 24 hrs. Effect of IK11 on
cell viability (C) in the presence and absence of theinhibitors was determined by the MTT assay. Data are
expressed as means ± SEM of three independent experi-
ments running in six parallels.
Another aliquot of HepG2 cells were treated (PJ34) or
not (CTRL) with 10 μM of PJ34 for 24 hrs in 6-well
plates. Percentage of cells in G1 (black bars), S (open
bars) and G2 +M (grey bars) phase of their cycle (D)
was assessed by measuring their respective DNA content
using a FACS Calibur flow cytometer. Results are
expressed in percentages of the total number of cells
means ± SEM of three independent experiments.
Small case Latin and Greek as well as capitalized Latin
letters above the bars indicate significant differences.
Means for a variable without a common letter of the
same case HepG2 cells were treated with 1000 times
diluted and type differ, P< 0.05.Results
IK11 inhibited migration, arrested cell cycle and induced
death of HepG2 carcinoma cells
It was previously demonstrated, that IK11 (Figure 1A) ef-
fectively killed A431 epidermoid carcinoma cell line [19].
To check its cytotoxicity on another tumor cell line, we
determined its dose response on HepG2 human hepato-
cellular carcinoma cells. We found that it killed HepG2
cells in a concentration dependent manner in the range of
0.1 to 10 μM (Figure 1B) with the EC50 value of
3.50± 0.68 μM. Interestingly, higher concentrations of
IK11 up to 25 μM did not increase cell death significantly
(data not shown) by the end of the 24 h incubation time.
We investigated the effect of IK11 on cell migration at a
concentration (1 μM) in which it induced only a slight cell
death (5%) by using a monolayer wound healing assay.
When the cells were incubated in 1000 times diluted
DMSO as vehicle control for 24 hrs, microscopic images
showed a marked decrease in the width of the wound
made by a pipette tip in confluent monolayer of cells indi-
cating strong migration. In the presence of 1 μM IK11,
the width of the wound remained almost identical to its
starting value (Figure 1C) indicating that IK11 effectively
inhibited migration of HepG2 cells at a concentration that
caused only a slight cell death. Latter effect is demon-
strated by the higher amount of floating debris in IK11
treated plates. We analyzed effect of 0.5 and 1 μM IK11
on the cell cycle. HepG2 cells were synchronized by over-
night serum deprivation, treated with 0.5 or 1 μM IK11
for 24 hrs, then DNA content of the cells was determined
by flow cytometry following propidium iodide staining. A
concentration dependent decrease was observed in the
number of G2 phase cells after the treatment with IK11
indicating that sublethal concentrations of IK11 prevented
the entry of the cells into their G2 phase (Figure 1D).
Figure 1 Effect of IK11 on cell migration, cell cycle and cell death.
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carcinoma cells
We determined apoptosis and necrosis by flow cytometry
following double staining of IK11-treated and untreated
cells with FITC-conjugated Annexin V and PI. We found
26.34% of apoptotic and 21.44% of necrotic cells upon
24 h IK11 treatment compared to 4.41% and 3.00% found
in control cells, respectively (Figure 2A,B). That means
that 10 μM IK11 induced a 5.972-fold and 7.147-fold in-
crease in apoptosis and necrosis, respectively.
IK11 depolarized the mitochondrial membrane of HepG2
carcinoma cells
Previously, it was found that IK11 induced caspase
mediated apoptosis in A431 cells [19], and we detected
both apoptosis and necrosis in IK11 treated HepG2 cells
(Figure 2B,C). Since mitochondrial depolarization can be
the consequence as well as the cause of both apoptotic and
necrotic cell death [22], we studied mitochondrial mem-
brane potential of control and IK11-treated (10 μM) cells
30 min after the start of treatment. After the treatment,
cells were loaded with the voltage-sensitive fluorescent
mitochondrial dye, JC1, then red and green fluorescence
was determined by flow cytometry (Figure 3A) or fluores-
cent microscopic images of the same field were taken in the
red and green channel (Figure 3B). Red to green shift of
JC1 fluorescence upon IK11 treatment detected by both
methods indicated that the drug induced depolarization of
the mitochondria as soon as 30 min after its application.N-acetylcysteine (NAC) abolished IK11-induced ROS
production, but hardly protected against death of HepG2
carcinoma cells
Mitochondrial depolarization impairs the efficacy of the
electron transport chain leading to massive ROS produc-
tion. Therefore, we measured endogenous ROS production
in IK11-treated and untreated HepG2 cells. We found, that
IK11 induced ROS production in a concentration
dependent manner in the range of 1 to 10 μM (Figure 4A)
as it was determined by a C400 fluorescent assay following
a 24 h incubation. To check whether ROS was a major
mediator of IK11-induced cell death, we investigated the
effect of 2 mM NAC on ROS production and cell death
induced by the drug. We found that NAC abolished IK11-
induced ROS production (Figure 4B), however, only
slightly increased viability of IK11 treated HepG2 cells
(Figure 4C). These observations suggested, that ROS pro-
duction was a marginal mediator of IK11-induced cell
death.
PJ34 prevented cell death and decreased ROS production
in IK11-treated HepG2 carcinoma cells
To investigate whether PARP activation could participate
in IK11-induced cell death, we applied three effective
PARP-inhibitors of different chemical structure as well
as silenced expression of the PARP gene by small inter-
fering RNA (siRNA) technique before incubating the
cells with IK11, and determined cell viabilities as well as
endogenous ROS production after 24 h incubation. We
Figure 2 Effect of IK11 on apoptosis and necrosis.
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IK11-induced cell death (Figure 5A). Effect of HO3089
and L2286, the two other PARP inhibitors on IK11-
induced cell death was similar to that of PJ34 (data not
shown). Furthermore silencing of PARP also diminished
IK11-induced cell death in about the same extent as the
PARP inhibitors did (Figure 5A) indicating that it was
most probably mediated via a PARP activation
dependent mechanism. In addition to its effect on cell
death, PJ34 significantly attenuated ROS production
induced by IK11 (Figure 5B), although PJ34 does not
have any ROS scavenging property. The other two PARP
inhibitors (data not shown) and silencing of PARP
(Figure 5B) diminished IK11 induced ROS production
similarly to PJ34.
Involvement of kinase signaling pathways in IK11-
induced death of HepG2 carcinoma cells
Many kinase signaling pathways including MAPKs and
Akt were shown to be involved in PARP-mediated cell
death [23]. Therefore, we investigated involvement of
these kinase cascades in the mechanism of IK11-induced
cytotoxicity. We observed activation of MAPKs but JNK1
as early as 10 min after application of 10 μM IK11 as it was
revealed by immunoblotting utilizing phosphorylation-
specific primary antibodies (data not shown). In case of
Erk1/2 and p38, this increased phosphorylation did not in-
crease any further (data not shown), while in case of JNK2,activation increased considerably during the following 6 h
of incubation (Figure 6A,B). JNK1 activation was not
affected by IK11 while activation of Akt was significantly
reduced by IK11 (Figure 6A,B). For verifying the involve-
ment of PARP activation in induction of JNK2 by IK11, we
applied 10 μM PJ34 in combination with the 10 μM IK11
for 6 h, then assessed kinase activation by immunoblot-
ting. We found that PJ34 inhibited IK11-induced activa-
tion of JNK2 and further reduced Akt phosphorylation
(Figure 6A,B). PJ34 in the absence of IK11 did not affect
JNK1 and JNK2 activation significantly, while it reduced
Akt phosphorylation more strongly than IK11 did
(Figure 6A,B). In order to establish physiological signifi-
cance of involvement of these kinases in IK11-induced cell
death, we applied inhibitors of them in combination with
IK11, and determined viability by using MTT assay of the
HepG2 cells 24 h after. We found that p38 and ERK inhibi-
tors did not affect (data not shown), while inhibition of
Akt by two different inhibitors only moderately attenuated
the cytotoxicity of IK11 (Figure 6C) indicating that activa-
tion of the Akt pathway could at least partially mediate
IK11-induced death of HepG2 carcinoma cells. Inhibition
of JNK pathway diminished the effect of IK11 in about the
same significant extent as PJ34 did (compare Figures 5A
and 6C) suggesting that JNK2 activation could be a major
mediator in the cytotoxicity of IK11. Cytotoxicity of IK11
was abolished by trans-resveratrol that has various, mostly
cytoprotective effects - in the concentration used by us -
Figure 3 Effect of IK11 on the mitochondrial membrane
potential.
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Akt (Figure 6C). In combination with the data in
Figure 4C, these data suggest that JNK2 activation was
most likely responsible for the IK11-induced death ofFigure 4 Effect of IK11 and NAC on endogenous ROS production andHepG2 carcinoma cells, however, combined inhibition of
JNK, Akt and ROS was necessary to completely protect
against it.
Contrary to previous studies utilizing oxidative stress
models, we found that phosphorylation of Akt in untreated
HepG2 cells was high, and PJ34 drastically decreased it
(Figure 6A,B). Therefore, we investigated the effect of PJ34
treatment on the cell cycle of HepG2 cells. As it is pre-
sented on Figure 6D, PJ34 prevented entry of the cells into
G2 phase of their cycle similarly as IK11 did (Figure 1D).Discussion
IK11 was previously found to kill A431 epidermoid car-
cinoma cells effectively [19]. In the present report we
determined its cytotoxic effect in the HepG2 human
hepatocellular carcinoma line. We found that IK11 at the
concentration of 1 μM prevented proliferation and entry
of the cells into their G2 phase. At higher concentrations
it killed the cells in a concentration dependent manner
by increasing both apoptosis and necrosis.
Mitochondria can promote cell death by various mechan-
isms depending on the severity of the stimulus to the mito-
chondrial membrane systems [15]. Depolarization that leads
to permeabilization of the outer mitochondrial membrane
could result in release of intermembrane pro-apoptotic pro-
teins including cytochrome c and apoptosis inducing factor,
causing caspase dependent and independent apoptosis, re-
spectively. On the other hand, permeabilization of both
membranes, e.g., by opening the permeability transition pore,
can lead to ATP depletion, swelling and disruption of mito-
chondria, and finally to necrotic cell death [15]. By using two
different methods, we demonstrated that IK11 induced
depolarization of the mitochondrial membrane as early as
30 min after its application, suggesting that both apoptotic
and necrotic cell death induced by the drug could be
mitochondria-mediated.
Impaired mitochondrial integrity causes malfunctioning
of the respiratory chain that in turn produces substantial
amount of ROS mainly at the level of cytochrome oxidase
[15]. Accordingly, we determined the effect of IK11 on
ROS production, and found that it induced production ofcell death.
Figure 5 Effect of IK11 and PJ34 on endogenous ROS
production and cell death.
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with the dose response of the drug on cell death. This sug-
gested that the killing of the hepatocellular carcinoma
cells could have been mediated by ROS originating from
malfunctioning mitochondria. However, in that case,Figure 6 Effect of IK11 and different inhibitors on the kinase signalinelimination of ROS by high concentration of NAC should
have protected the HepG2 cells from IK11-induced death.
As we found, NAC indeed eliminated IK11-induced ROS
production, but only slightly diminished cell death, indicat-
ing ROS was only a marginal mediator. In contrast, PJ34,
an effective inhibitor of PARP that does not have any
ROS-scavenging property, diminished both ROS produc-
tion and cell death induced by 2.5-10 μM IK11 almost to
the level of untreated cells. Furthermore, silencing of the
expression of PARP gene by siRNA attenuated IK11
induced ROS production in about the same extent as PJ34
and two other PARP inhibitors did. These results clearly
verified that ROS-production was a phenomenon accom-
panying cell death rather than a major mediator of it under
our experimental conditions. Furthermore, it indicated sig-
nificant involvement of PARP-activation in IK11-induced
death of the hepatocellular carcinoma cells.
Activation of MAPK and the PI3K-Akt pathways is con-
sidered to be directly or indirectly involved in extra-
nuclear effects of PARP-activation [8,24,25]. MAPK path-
ways, which consist of the ERK1/2 the JNK and the p38
pathways, govern cell proliferation, differentiation, stress
responses, and survival, among other functions. JNK and
p38 were found to be involved in oxidative stress, inflam-
matory conditions, cytokine production, and can induce
apoptosis under numerous experimental conditions. In
contrast, Erk1/2 is thought to possess both apoptotic and
antiapoptotic properties and it was shown to be involved
in the regulation of cell migration [26]. Additionally, it has
been suggested that JNK has targets in the mitochondria
and that mitochondrial JNK activation in response to ROSg pathways and cell death.
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plays a key role in multiple cellular processes such as cell
proliferation, apoptosis and cell migration, oxidative stress
and it is thought to be involved in survival pathways by
inhibiting apoptotic processes, e.g., via inhibition of the
MAPK pathways. Similarly to ERK, the PI3K-Akt pathway
is considered to be cytoprotective, although in certain sys-
tems it was found to mediate apoptosis [28]. Accordingly,
many compounds possessing apoptotic properties were
found to activate the MAPK pathways and inhibit the
PI3K-Akt pathway, leading to decreased cell migration
and proliferation or to the death of the cell.
Under our experimental conditions, we found activation
of the MAPKs but JNK1 as early as 10 min after the
addition of IK11. Since their activation preceded mito-
chondrial depolarization, early activation of these signaling
kinases could trigger the mitochondrial-dependent death
of hepatocellular carcinoma cells. Out of the kinases stud-
ied, JNK2 activation was sustained during longer incuba-
tion with IK11. Interestingly, JNK2 but not JNK1
activation was found to be involved in high arsenite con-
centration induced DNA damage mediated apoptosis [29].
The similar pattern of JNK activation suggests that IK11
induced death of HepG2 cells could be mediated by DNA
damage that could trigger PARP activation leading to
mitochondrial depolarization mediated cell death. Attenu-
ation of JNK2 activation by PJ34 as well as failure by NAC
to protect against IK11 induced cell death, support such
mechanism.
Very recently, a strong correlation was found between
Akt activation and increased proliferation potential of
HepG2 cells [30]. Accordingly, we found quite high activa-
tion of Akt in untreated HepG2 cells that was diminished
by IK11 and PJ34 too. These results are consistent with re-
cent reports [28,29], however, contrary to those that we
and others found in oxidative stress models indicating
again that the mechanism of IK11 induced cell death
could differ considerably from that of oxidative stress.
To verify the exact role of the kinase pathways, we ap-
plied selective inhibitors of them and measured IK11-
induced cell death in their presence. We found that
pharmacological inhibition of PI3K-Akt pathway only
moderately increased survival of IK11-treated cells while
that of p38 and ERK did not have any significant effect.
On the other hand, the JNK-inhibitor SP-600125 signifi-
cantly, and trans-resveratrol completely, protected the
hepatocellular carcinoma cells from the toxic effects of
IK11. These results are significant in several aspects.
First, PI3K-Akt is considered antiapoptotic kinase sig-
naling pathway since it was previously found to be active
in several human cancers and its inappropriate activation
or inhibition resulted in blocked proliferation and
enhanced sensitivity toward cytotoxic agents. One major
mechanism by which this antiapoptotic effect is mediatedis phosphorylation of Ser83 of apoptosis signal-regulating
kinase 1 (ASK1) by Akt, rendering this pro-apoptotic kin-
ase inactive [31]. However, Akt-mediated phosphorylation
of ASK1 at Thr838 activates ASK1 and causes the subse-
quent downstream activation of p38 MAPK, leading to
apoptosis [31]. We found inhibition of Akt upon IK11
treatment and moderately increased cell survival when the
PI3K-Akt pathway was blocked at two different levels,
namely at PI3K and Akt by two separate selective inhibi-
tors, indicating that this pathway was a minor mediator of
IK11-induced cell death. Furthermore, we found that PJ34
inhibited the entry of HepG2 cells into the G2 phase of
their cycle similarly as IK11 did that could be the result of
attenuated activation of Akt by these substances.
Second, activation of JNK is thought to trigger mito-
chondrial depolarization-mediated apoptotic cell death
[27]. In a complete agreement with this result, we found
that inhibition of JNK2 substantially inhibited the death
of hepatocellular carcinoma cells induced by IK11.
Third, we found that inhibition of PARP decreased acti-
vation of JNK2 and prevented IK11-induced cell death,
suggesting a strong relationship between activation of
PARP and JNK2. In a recent separate study, we found that
early activation of MAPKs, mediating cell death in oxida-
tive stress, is compensated by increased expression of
MKP-1, and inhibition of PARP augmented MKP-1 ex-
pression, resulting in cytoprotection, which was prevented
by silencing MKP-1 [13]. It is likely that a similar mechan-
ism was involved in the observed correlation between
PARP and JNK2 activation in the IK11-induced, mito-
chondrial depolarization-mediated death of hepatocellular
carcinoma cells.
Finally, the observation that trans-resveratrol abolished
the cytotoxic effect of IK11 indicated that Akt and JNK2 ac-
tivation as well as ROS production were all involved in this
effect, although JNK2 activation seemed to be the major
mediator of it.Conclusion
Activation of JNK2 led to mitochondrial depolarization-
mediated necrotic and apoptotic death of IK11-treated
hepatocellular carcinoma cells that were prevented to dif-
ferent extents by inhibitors of Akt, JNK and PARP. These
results indicate a pro-apoptotic role of Akt in this system,
and raise attention to a novel mechanism that should be
considered when cancer therapy is augmented with
PARP-inhibition, namely cytoprotection by inhibition of
JNK2.
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